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Edited by Ned ManteiAbstract We previously showed that the zinc ﬁnger-containing
transcription factor Kru¨ppel-like factor 5 (KLF5) is important in
mediating transformation by oncogenic H-Ras through induction
of cyclin D1 expression and acceleration of the G1/S transition of
the cell cycle. Here we present evidence of a role for KLF5 in
accelerating mitotic entry in H-Ras-transformed NIH3T3 ﬁbro-
blasts. When compared with non-transformed parental NIH3T3
cells, H-Ras-transformed ﬁbroblasts exhibit an increase in mito-
tic index, levels of cyclin B1 and Cdc2, and cyclin B1/Cdc2
kinase activity. Inhibition of KLF5 expression in H-Ras-trans-
formed cells with KLF5-speciﬁc small interfering RNA (siRNA)
results in a decrease in each of the aforementioned parameters,
with a concomitant reduction in the transforming potential of
the cells. Conversely, over-expression of KLF5 in NIH3T3 cells
leads to an increase in the promoter activity of the genes encod-
ing cyclin B1 and Cdc2. These results indicate that KLF5
accelerates mitotic entry in H-Ras-transformed cells by trans-
criptionally activating cyclin B1 and Cdc2, which leads to an
increase in cyclin B1/Cdc2 kinase activity. Extending our previ-
ous observation that KLF5 activates cyclin D1 transcription to
promote G1/S transition, our current results further support a
crucial function for KLF5 in mediating cellular transformation
caused by oncogenic H-Ras.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Kru¨ppel-like factors (KLFs) are Sp1-like transcription fac-
tors that bear signiﬁcant homology to the Drosophila melano-
gaster segmentation gene, Kru¨ppel [1–5]. Proteins of this
family contain a DNA binding domain consisting of C2H2 zincAbbreviations: DMEM, Dulbeccos modiﬁed Eagles medium; FACS,
ﬂuorescence-activated cell sorting; FBS, fetal bovine serum; KLF5,
Kru¨ppel-like factor 5; MAPK, mitogen-activated protein kinase;
MPM2, mitotic phosphoepitope marker 2; PBS, phosphate-buﬀered
saline; PI, propidium iodide; siRNA, small interfering RNA
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doi:10.1016/j.febslet.2005.07.053ﬁngers and exhibit important regulatory functions [2–5]. Two
related, yet functionally contrasting, members of the KLF
family, KLF4 and KLF5, are diﬀerentially expressed in the
intestinal epithelium [3,6]. While KLF4 is predominantly ex-
pressed in the post-mitotic, terminally diﬀerentiated epithelial
cells of the intestinal villi [7,8], KLF5 is mostly expressed in
the undiﬀerentiated, proliferating cells of the crypt compart-
ment [9]. Studies support a role for KLF4 in functioning as
a tumor suppressor of the intestinal epithelial cells [10,11]. In
contrast, KLF5 has been shown to accelerate cell proliferation
in both cultured ﬁbroblasts and intestinal epithelial cells
[12–14].
Ras proteins are a family of small GTPases often found to
be constitutively activated in tumors. For example, activating
K-Ras mutations are found in approximately 90% of pancre-
atic and 50% of colon carcinomas [15,16]. Oncogenic Ras iso-
forms cause the constitutive activation of a signaling cascade
involving several proteins including Raf and the mitogen-
activated protein kinase (MAPK) [17–19]. Expression of these
Ras isoforms can lead to a transformed phenotype in various
cell lines, including ﬁbroblasts [12,20] and epithelial cells [21].
Previous experiments demonstrate that constitutive activation
of the Ras pathway accelerates the G1/S transition of cell cycle
through induction of cyclin D1 expression [13,22,23]. Conse-
quently, oncogenic Ras-mediated transformation leads to ser-
um- and anchorage-independent growth and increased
metastatic potential [12,24,25]. A recent study reveals that
oncogenic Ras also accelerates the G2/M progression of the
cell cycle by increasing the level of cyclin B1 protein [26]. Of
note is the G2/M progression is rigorously controlled by the
activity of the cyclin B1/Cdc2 kinase complex [27,28].
We recently showed that the level of KLF5 is increased in
NIH3T3 ﬁbroblasts transformed by oncogenic H-Ras [13].
This increase is the result of H-Ras-induced activation of
MAPK and subsequent induction of the gene encoding early
growth response 1 (Egr1), which transcriptionally activates
KLF5 [13]. Activated KLF5 then leads to the transcriptional
induction of the gene encoding cyclin D1 [13]. Importantly,
inhibition of KLF5 expression is accompanied by a reduction
in the transforming potential of the cells, including a reduced
capacity for anchorage-independent growth [13]. Here we
present evidence for an equally important role of KLF5 in
accelerating mitotic entry of H-Ras-transformed NIH3T3
ﬁbroblasts through activation of the cyclin B1/Cdc2 kinase
complex.blished by Elsevier B.V. All rights reserved.
Fig. 1. KLF5 increases mitotic activity in oncogenic H-Ras-trans-
formed NIH3T3 cells. (A) NIH3T3 cells, untransfected Ras7 cells, and
Ras 7 cells transfected with non-speciﬁc (NS) control siRNA or KLF5-
speciﬁc siRNA from day 1 to day 3 were stained with the Hoechst
33258 dye to label those cells in mitosis. The mitotic index is the percent
of cells in mitosis among a total of 500 cells counted. N = 4; **P < 0.01
by two-tailed Students t test. (B) Cells were immuno-stained with a
phospho-histone H3 antibody to label mitotic cells. Hoechst dye was
used to stain nuclei. Mitotic index is represented as percent of phospho-
histone H3-positive cells among a total of 1000 cells counted. N = 3;
*P < 0.05; **P < 0.01 by two-tailed Students t test.
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2.1. Cell lines and reagents
Culture media and fetal bovine serum (FBS) were purchased from
Mediatech, Inc. (Herndon, VA). The expression construct containing
the oncogenic H-Ras was generously provided by Dr. Raul Urrutia
[29]. The monoclonal antibody against Cdc2 and Actin were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA) and EMD Biosci-
ences (San Diego, CA), respectively. A polyclonal antibody against cy-
clin B1 was acquired from Rockland Immunochemicals (Gilbertsville,
PA). Antibodies against phospho-histone H1 and histone H1 were ob-
tained from EMD Biosciences (San Diego, CA) and Upstate USA
(Charlottesville, VA), respectively. The mouse monoclonal antibody
directed against phospho-Ser/Thr-Pro MPM2 (mitotic phosphoepitope
marker-2) was purchased from Upstate USA. FITC-conjugated anti-
mouse IgG (Fc-speciﬁc) secondary antibodies were purchased from
Sigma (St. Louis, MO). The antibody against phosphorylated histone
H3 (Serine-10) was purchased as part of Mitotic Index Hitkit from Cel-
lomics, Inc (Pittsburgh, PA). The 287 cyclin B1 promoter luciferase
reporter was generously provided by Dr. Karen Katula [30,31]. The
luciferase construct with Cdc2 promoter was generously provided by
Dr. Christopher Glass [32].
2.2. Cell lines
NIH3T3 mouse ﬁbroblasts were maintained in Dulbeccos modiﬁed
Eagles medium (DMEM) supplemented with 10% FBS and 1% peni-
cillin–streptomycin at 37 C in a 5% CO2 atmosphere. Stable clones of
NIH3T3 transformed by oncogenic H-Ras were selected from foci
formed in soft agar as described previously [12]. A representative
clone, called Ras7, was used in the previous and current studies [13].
2.3. Cell cycle analysis
Fractions of cells at diﬀerent phases of the cell cycle were analyzed as
previously described [33]. In brief, cells were collected and resuspended
in 70% ethanol overnight at 20 C. Before analysis, cells were pelleted
again and incubated with a phospho-Ser/Thr-Pro MPM2 monoclonal
antibody diluted in Dulbeccos phosphate-buﬀered saline for 1 h and
then with a FITC-conjugated anti-mouse secondary antibody for
30 min. Cells were then resuspended in a propidium iodide (PI) solu-
tion consisting of 50 lg/ml PI, 50 lg/ml RNase A, 0.1% Triton X-
100 and 0.1 mM EDTA for 15 min. Cells were then sorted using a
FACSCalibur ﬂow cytometer (BD Biosciences, San Jose, CA).
2.4. Cdc2 activity assays
Cdc2 kinase activity was measured as previously described [31]. Cells
were lysed using a cell lysis buﬀer purchased from Cell Signaling Tech.
(Beverly, MA) supplemented with a protease inhibitor cocktail pur-
chased from Roche (Indianapolis, IN). The cell extracts were then
immunoprecipitated using a Cdc2 monoclonal antibody and protein
G-conjugated sepharose beads (Sigma, St. Louis, MO). The pellets
were then washed thrice with lysis buﬀer and then incubated for
30 min at 37 C with 20 mM HEPES, pH 7.9, 5 mM MgCl2, 1 lg his-
tone H1 (Roche), 1 mM EDTA and 100 lM ATP in a total volume of
20 ll. The samples were then examined by Western blotting using anti-
bodies against phospho-histone H1 and histone H1.
2.5. siRNA transfection
Cells were transfected with small interfering RNA (siRNA) using a
protocol similar to that described previously [13]. The KLF5-speciﬁc
siRNA was designed to target against sequences corresponding to
nucleotides between 875 and 895 of the coding region of mouse
KLF5 (GenBank Accession No. NM_009769). Control siRNA was
also described previously [13]. Cells were cultured in 100-mm culture
dishes until 40% conﬂuent and then transfected with siRNA in Opti-
MEM with reduced serum content (Invitrogen, Carlsbad, CA) using
the Oligofectamine transfection reagent (Invitrogen) for 4 h. The cells
were then provided with DMEM containing 10% FBS and 1% penicil-
lin–streptomycin.
2.6. Measurement of mitotic indices
Mitotic indices were measured using Hoechst 33258 stain and phos-
pho-histone H3 (Ser-10) antibodies. Cells were ﬁrst ﬁxed in a 3% form-
aldehyde solution in phosphate-buﬀered saline (PBS) for 15 min. ForHoechst staining, cells were then incubated at room temperature for
20 min after the addition of cold 100% methanol. After rinsing with
PBS, a Hoechst 33258 solution was added to a ﬁnal concentration of
0.2 lg/ml and samples were incubated at room temperature for
15 min. Samples are then rinsed again with PBS and nuclei were visu-
alized using an inverted ﬂuorescence microscope (Nikon, Melville,
NY). Mitotic index was scored as the number of mitotic cells (with
condensed nuclei) among a total population of 500 stained cells. For
staining with anti-phospho-histone H3, protocol described in the Mito-
tic Index Hitkit (Cellomics, Pittsburgh, PA) was applied. In brief, cells
were permeabilized using a permeabilization buﬀer after ﬁxing cells
with 3.7% formaldehyde solution, for 15 min. After rinsing with block-
ing solution, cells were then incubated with the primary antibody fol-
lowed by the staining solution (containing Alexa 488 labeled secondary
antibody and Hoechst dye) for 1 h each. Cells were then washed and
nuclei were visualized using a ﬂuorescent microscope. Mitotic index
was scored as the number of phospho-histone H3-positive cells among
a total population of 1000 cells counted.3. Results
3.1. H-Ras-transformed NIH3T3 ﬁbroblasts exhibit an increase
in mitotic index, which is decreased by inhibition of KLF5
A clonal derivative of H-Ras-transformed NIH3T3 ﬁbro-
blasts, called Ras7 [13], was transfected with KLF5-speciﬁc
or non-speciﬁc siRNA and examined daily for mitotic indices
using several independent methods. The non-transformed
parental NIH3T3 cells and untransfected Ras7 cells were used
as controls. Fig. 1 shows that the mitotic index, as measured by
either Hoechst 33258 staining (Fig. 1A) or phospho-histone
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when compared with the non-transformed parental NIH3T3
cells on all 3 days of culture. Transfection of Ras7 cells with
KLF5-speciﬁc siRNA resulted in a signiﬁcant reduction in mi-
totic index when compared to untransfected or control siRNA-
transfected Ras7 cells.
To provide an additional means of measuring mitosis, we
immuno-stained cells with a phospho-MPM2 antibody and
sorted cells by FACS following staining with PI [33,34]. As
shown in Fig. 2A, the population of MPM2-positive cells
was signiﬁcantly greater in Ras7 cells as compared to non-
transformed NIH3T3 cells on days 2 and 3 of culturing. Again,
transfection of Ras7 cells with KLF5-speciﬁc siRNA, but not
non-speciﬁc siRNA, signiﬁcantly reduced the proportion of
MPM2-positive cells when compared to untransfected Ras7
cells. A similar ﬁnding is observed when the ratios between
cells in the M and G2/M phase of the cell cycle were measured
(Fig. 2B). These results indicate that KLF5 is responsible for
the increase in mitotic index and acceleration in the G2/M tran-
sition of the cell cycle in Ras7 cells.
3.2. H-Ras-mediated transformation of NIH3T3 ﬁbroblasts is
accompanied by an increase in the levels of cyclin B1 and
Cdc2, and cylinB1/Cdc2 kinase activity, all of which are
decreased by inhibition of KLF5
As mitosis is controlled by cyclin B1 and Cdc2 [27,28], we
measured KLF5, cyclin B1 and Cdc2 protein levels in NIH3T3Fig. 2. KLF5 accelerates G2/M transition of the cell cycle in H-Ras-
transformed NIH3T3 cells. (A) Immuno-staining was performed with
a phospho-Ser/Thr-Pro MPM2 antibody to identify cells in the M
phase of cell cycle. Cells were then stained with PI to measure the
DNA content and subjected to FACS analysis. The percentages of
MPM2-positive cells among all cells analyzed were plotted at diﬀerent
time points. N = 3; *P < 0.05; **P < 0.01 by two-tailed Students t test.
(B) The ratio of M-phase population to G2/M-phase population was
calculated by dividing the number of MPM2-positive cells by those in
the G2/M phase (i.e., cells with a DNA content of 4N). N = 3;
*P < 0.05; **P < 0.01 by two-tailed Students t test.and Ras7 cells, as well as Ras7 cells treated with KLF5-speciﬁc
siRNA or control siRNA, by Western blot analysis. As shown
in Fig. 3A, Ras7 cells contained a higher level of KLF5, cyclin
B1 and Cdc2 than NIH3T3 cells (compare lane 2 to lane 1).
Transfection of Ras7 cells with KLF5-speciﬁc siRNA resulted
in a reduction in the level of KLF5 and a concomitant reduc-
tion in the levels of cyclin B1 and Cdc2 (Fig. 3A, lane 4). In
contrast, transfection of Ras7 cells with control non-speciﬁc
siRNA did not change the levels of any of the three proteins
(Fig. 3A, lane 3). Importantly, Fig. 3B shows that Ras7 cells
contained a higher level of cyclin B1/Cdc2 kinase activity than
NIH3T3 cells (compare lane 2 to lane 1) and that this increase
was reduced in Ras7 cells treated with KLF5-speicﬁc siRNA
but not control siRNA (compare lane 4 to lane 3). These re-
sults indicate that KLF5 is responsible for the increased cyclinFig. 3. Eﬀect of KLF5 inhibition by siRNA on cyclin B1, Cdc2, and
cyclin B1/Cdc2 kinase activity in H-Ras transformed cells. (A) The
levels of KLF5, cyclin B1, and Cdc2, in NIH3T3 cells, untransfected
Ras7 cells, and Ras7 cells transfected with non-speciﬁc (NS) control
siRNA or KLF5-speciﬁc siRNA, were determined by Western blot
analysis. Actin serves as a loading control. (B) The cyclin B1/Cdc2
kinase activity was measured by immunoprecipitation with a Cdc2
antibody followed by in vitro kinase reaction using histone H1 as a
substrate. P-histone H1 is the phosphorylated product.
Fig. 4. KLF5 increases cyclin B1 and Cdc2 promoter activity.
NIH3T3 cells were co-transfected with a luciferase plasmid containing
cyclin B1 promoter (cyclin B1 promoter-luc) [30] or Cdc2 promoter
(Cdc2 promoter-luc) [32] and either a control vector (pMT3 vector) or
with a KLF5-expression vector (pMT3-KLF5). Luciferase activity was
determined 2 days following transfection and normalized to the
internal control, Renilla luciferase. N = 4; **P < 0.001 when compared
to PMT3 vector-transfected cells using two-tailed Students t test.
Oncogenic H-Ras
Transformation
MAPK
Egr-1
KLF5
Cyclin D1 Cyclin B1/Cdc2
Accelerated Cell Cycle
Fig. 5. A model for the role of KLF5 in mediating H-Ras-induced
transformation. The induction of KLF5 by H-Ras is mediated by
MAPK and Egr-1 as previously demonstrated [13]. KLF5 then
activates the transcription of the genes encoding cyclin D1 [13] and
cyclin B1/Cdc2 (this study). The combined eﬀect is an acceleration of
the cell cycle, which eventually results in cellular transformation.
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observed increase in mitotic activity in Ras7 cells.
3.3. KLF5 activates cyclin B1 and Cdc2 promoter activity
To determine the mechanism by which KLF5 increases cy-
clin B1 and Cdc2, we conducted co-transfection experiments
using a KLF5-expression vector and a luciferase reporter con-
struct containing the cyclin B1 or Cdc2 promoter. Cells co-
transfected with an empty vector served as a control. As seen
in Fig. 4, cells transfected with the KLF5-expression vector
exhibited signiﬁcantly higher activities from both cyclin B1
and Cdc2 promoters when compared to those transfected with
the empty vector. These results indicate that KLF5 is a tran-
scriptional activator of the cyclin B1 and Cdc2 genes.4. Discussion
Cellular transformation caused by oncogenic Ras is charac-
terized by increased cell proliferation, loss of contact inhibition
and anchorage-independent cell growth [35,36]. Cell prolifera-
tion is generally associated with accelerated G1/S and G2/M
cell cycle transitions [37]. The response of the G1/S cell cycle
machinery to Ras-induced MAPK stimulation is well estab-
lished, consisting of the upregulation of cyclins D [23,38], E
[39], and A, as well as their corresponding cyclin dependent ki-
nases (Cdks) [40]. There is also evidence that the Ras signaling
cascade can accelerate the G2/M transition [41,42].
Ample evidence indicates that cyclin B1 is an important pro-
tein regulating proliferation. Depletion of cyclin B1 is found to
inhibit proliferation and induce apoptosis in human tumor
cells [43]. Previous studies also demonstrate that cyclin B1 is
crucial for mediating oncogenic H-Ras-induced transforma-
tion [26,41]. The onset of mitosis in the cell is strictly regulated
by several factors, among them cyclin B1 and Cdc2 [27,44].
The results of our study, which demonstrate that H-Ras-trans-formed ﬁbroblasts exhibit increased cyclin B1/Cdc2 protein
levels and activity, as well as increased mitotic index, are con-
sistent with these previous ﬁndings.
We previously reported that transformation by oncogenic
H-Ras results in an increase in the rate of cell proliferation
and the S-phase population of cells [13]. In H-Ras-transformed
cells, KLF5 is up-regulated due to H-Ras-activated MAPK
and the increased KLF5 is responsible for an increase in cyclin
D1 expression at the transcriptional level [13]. This leads to
accelerated proliferation. In the current study, we identiﬁed cy-
clin B1 and Cdc2 as two novel targets of KLF5 upon its induc-
tion by H-Ras (Figs. 3A and 4). Consequently, there is an
increase in cyclin B1/Cdc2 kinase activity, which becomes
inhibited upon treatment of H-Ras-transformed cells with
KLF5-speciﬁc siRNA (Fig. 3B). Importantly, inhibition of
KLF5 expression in H-Ras-transformed cells results in a reduc-
tion of mitotic index and the M-to-G2/M ratio of cells (Figs. 1
and 2). These results demonstrate that KLF5 serves a crucial
function in mediating the biological activity of H-Ras in accel-
erating the G2/M transition, an event which promotes cellular
transformation. A model describing the signal pathway as elic-
ited by oncogenic H-Ras and mediated by KLF5 is illustrated
in Fig. 5.
KLF5 has previously been shown to exert a pro-proliferative
eﬀect on non-transformed NIH3T3 ﬁbroblasts and intestinal
epithelial cells including IEC-6, IEC-18, and IMCE [12,45].
Stable expression of KLF5 in NIH3T3 cells has also been
shown to result in a transformed phenotype including in-
creased proliferation and anchorage-independent growth [12].
In addition, all-trans retinoic acid (ATRA) inhibits prolifera-
tion of IEC-6 cells by inhibiting KLF5 gene expression [14].
In contrast, over-expression of KLF5 in several human cancer
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Thus, KLF5 may exhibit diﬀerent functions at diﬀerent stages
of tumor formation. It is of interest to note that a reason for
KLF5s pleiotropic eﬀect may be its diﬀerential regulation by
the ubiquitin–proteasome pathway in non-transformed and
cancer cells [47]. Nonetheless, the exact mechanism by which
KLF5 aﬀects growth of cancer cells remain to be established.
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